Print Page

给 业 界 的 信
 
FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis (Letter to Healthcare Professionals) (English only)
 
 
 
附件:
  1. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis (English only)  
Related Information:
中国：国家药监局关于修订孟鲁司特制剂说明书的公告（2025年第120号） 上载于 2025-12-23
Australia: More prominent safety warnings about the neuropsychiatric effects of ... 上载于 2025-01-17
The United Kingdom: Montelukast: reminder of the risk of neuropsychiatric reacti... 上载于 2024-04-30
Singapore: Advisory on restriction on the use of montelukast and neuropsychiatri... 上载于 2020-12-11
Singapore: Advisory on restriction on the use of montelukast and neuropsychiatri... 上载于 2020-10-31
The United States: FDA requires Boxed Warning about serious mental health side e... 上载于 2020-03-05
The United Kingdom: Montelukast (Singulair): reminder of the risk of neuropsychi... 上载于 2019-09-20
Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions (Let... 上载于 2019-09-20
台湾: 卫生福利部食品药品管理署提醒医疗人员及病患谨慎使用气喘治疗药物Montelukast 上载于 2018-07-28
澳洲：安全审查：孟鲁司特 上载于 2018-07-13
Updated information regarding neuropsychiatric events on leukotriene inhibitors:... 上载于 2009-06-15
 
back